| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5178694
Max Phase: Preclinical
Molecular Formula: C17H22O3
Molecular Weight: 274.36
Associated Items:
Representations
Canonical SMILES: CCCCCCCc1ccc(C(=O)/C=C/C(=O)O)cc1
Standard InChI: InChI=1S/C17H22O3/c1-2-3-4-5-6-7-14-8-10-15(11-9-14)16(18)12-13-17(19)20/h8-13H,2-7H2,1H3,(H,19,20)/b13-12+
Standard InChI Key: PEOVWOYAVKZVNZ-OUKQBFOZSA-N
Associated Targets(Human)
Cysteine protease ATG4B 985 Activities
Phospholipase A2 group 1B 720 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 274.36 | Molecular Weight (Monoisotopic): 274.1569 | AlogP: 4.02 | #Rotatable Bonds: 9 |
| Polar Surface Area: 54.37 | Molecular Species: ACID | HBA: 2 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 3.26 | CX Basic pKa: | CX LogP: 4.89 | CX LogD: 1.46 |
| Aromatic Rings: 1 | Heavy Atoms: 20 | QED Weighted: 0.42 | Np Likeness Score: 0.31 |
References
| 1. Kudo Y, Endo S, Fujita M, Ota A, Kamatari YO, Tanaka Y, Ishikawa T, Ikeda H, Okada T, Toyooka N, Fujimoto N, Matsunaga T, Ikari A.. (2022) Discovery and Structure-Based Optimization of Novel Atg4B Inhibitors for the Treatment of Castration-Resistant Prostate Cancer., 65 (6.0): [PMID:35244402] [10.1021/acs.jmedchem.1c02113] |
Source
Source(1):